selected scholarly activity
-
chapters
- Combining Oncolytic Viruses with Cancer Immunotherapy. 339-355. 2011
-
conferences
- Chromatography Purification Methods for Rhabdoviral Vectors. Molecular Therapy. 412-412. 2019
- Viral sensitizers potential infection of cancer cells via NF-kappaB. European Journal of Cancer. S22-S23. 2019
- Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.. Journal of Clinical Oncology. e14637-e14637. 2017
- Development of a Monolithic Chromatography-Based Manufacturing Process for Clinical-Grade Viral Vectors. Molecular Therapy. 223-223. 2017
- Addressing the downstream challenges of viral therapy for cancer treatment - a study of rhabdoviral vector purification. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2017
- 713. Optimization and Scale-Up of a Manufacturing Process for Clinical-Grade Adenovirus-Based Vectors. Molecular Therapy. S281-S281. 2016
- Abstract A53: Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment.. Clinical Cancer Research. A53-A53. 2016
- Abstract B077: Evaluating oncolytic vaccines targeting mutated epitopes in a murine fibrosarcoma model CMS-5. Cancer immunology research. B077-B077. 2016
- Abstract B096: Oncolytic vaccination for HPV induced cancer. Cancer immunology research. B096-B096. 2016
- USE OF ONCOLYTIC VIRAL VACCINES TO TREAT CANCER. Anticancer Research. 6029-6030. 2014
- Development of a Manufacturing Process for an Oncolytic Vaccine. Human Gene Therapy. A49-A49. 2012
- Large-Scale Production of a Maraba-Based Oncolytic Virus. Molecular Therapy. S224-S224. 2012
- Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis. 211-217. 2006
- EBV detection in sequential biopsies from patients with recurrent acute allograft rejections and relationship to posttransplant lymphoproliferative disorder.. Blood. 354B-354B. 2001
- Vesicular stomatitis virus infects and kills human leukemic cells while sparing normal bone marrow progenitors.. Gene Therapy. S9-S9. 2001
- Identification of vesicular stomatitis virus as a leukemolytic agent.. Blood. 213B-213B. 2000
- Alternative splicing leads to the frequent co-expression of p190BCR-ABL and p210BCR-ABL transcripts in the chronic phase of chronic myelogenous leukemia.. Blood. 912-912. 1996
- MOLECULAR CHARACTERIZATION OF A TRANSLOCATION IN A NEUROBLASTOMA-DERIVED CELL-LINE INVOLVING THE PROMOTER REGION OF A HOMEOBOX GENE. Journal of Cellular Biochemistry. 192-192. 1994
-
journal articles
- Comparison of the performance of anion exchange membrane materials for adenovirus purification using laterally-fed membrane chromatography. Biochemical Engineering Journal. 182:108417-108417. 2022
- Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. Journal for ImmunoTherapy of Cancer. 10:e003923-e003923. 2022
- Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 185:896-915.e19. 2022
- Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI insight. 7:e155655. 2022
- CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX. Frontiers in Immunology. 13:1050250. 2022
- A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer. Cancer Immunology, Immunotherapy. 70:3451-3460. 2021
- CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. Journal for ImmunoTherapy of Cancer. 9:e003329-e003329. 2021
- Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nature Communications. 12:2626. 2021
- Probing effects of additives on the filterability of oncolytic viruses via a microfiltration process. Journal of Membrane Science. 620:118783-118783. 2021
- RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. Communications Biology. 4:102. 2021
- Integrated development of enzymatic DNA digestion and membrane chromatography processes for the purification of therapeutic adenoviruses. Separation and Purification Technology. 254:117503-117503. 2021
- Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers. OncoImmunology. 10:1885778. 2021
- Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology. 20:615-632. 2020
- Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo. Scientific Reports. 10:13349. 2020
- Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. Journal for ImmunoTherapy of Cancer. 8:e000981-e000981. 2020
- Measles Vaccines Designed for Enhanced CD8+ T Cell Activation. Viruses. 12:242-242. 2020
- Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. Methods in molecular biology (Clifton, N.J.). 2058:191-211. 2020
- Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. Journal for ImmunoTherapy of Cancer. 7:189. 2019
- Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. Journal of Clinical Investigation. 129:5400-5410. 2019
- Purification of therapeutic adenoviruses using laterally-fed membrane chromatography. Journal of Membrane Science. 579:351-358. 2019
- Excipient selection for thermally stable enveloped and non-enveloped viral vaccine platforms in dry powders. International Journal of Pharmaceutics. 561:66-73. 2019
- Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. OncoImmunology. 8:e1512329. 2019
- Transforming the prostatic tumor microenvironment with oncolytic virotherapy. OncoImmunology. 7:e1445459-e1445459. 2018
- Consecutive Spray Drying to Produce Coated Dry Powder Vaccines Suitable for Oral Administration. ACS Biomaterial Science and Engineering. 4:1669-1678. 2018
- Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. OncoImmunology. 7:e1423171-e1423171. 2018
- Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine. 36:2181-2192. 2018
- Sterile filtration of oncolytic viruses: An analysis of effects of membrane morphology on fouling and product recovery. Journal of Membrane Science. 548:239-246. 2018
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine. 10:eaao1641. 2018
- Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virotherapy. Volume 7:117-128. 2018
- Infectious Optimism following the 10th International Oncolytic Virus Meeting. Molecular Therapy - Oncolytics. 7:12-16. 2017
- Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats. Scientific Reports. 7:15738. 2017
- Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer immunology research. 5:847-859. 2017
- Driving Large T cell Responses with an Oncolytic Viral Vaccine. Journal of Pharmacy and Pharmaceutical Sciences. 20:10S-11S. 2017
- Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine. 9:31-36. 2016
- Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. Journal of Immunology. 196:4587-4595. 2016
- S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3. Nature Immunology. 17:514-522. 2016
- Cancer immunology and canine malignant melanoma: A comparative review. Veterinary Immunology and Immunopathology. 169:15-26. 2016
- Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE. 11:e0159471-e0159471. 2016
- Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE. 11:e0155947-e0155947. 2016
- Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy. Journal of Controlled Release. 220:210-221. 2015
- VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell. 28:210-224. 2015
- Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature Medicine. 21:530-536. 2015
- Microvesicles: ubiquitous contributors to infection and immunity. Journal of Leukocyte Biology. 97:237-245. 2015
- Going viral with cancer immunotherapy. Nature Reviews Cancer. 14:559-567. 2014
- Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. Molecular Therapy. 22:1320-1332. 2014
- Erratum. Immunotherapy. 6:657-658. 2014
- Evolution of oncolytic viruses: novel strategies for cancer treatment (vol 5, pg 1191, 2013). Immunotherapy. 6:657-658. 2014
- Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy. 22:420-429. 2014
- Human Coronavirus OC43 Nucleocapsid Protein Binds MicroRNA 9 and Potentiates NF-κB Activation. Journal of Virology. 88:54-65. 2014
- Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. Molecular Therapy. 22:123-131. 2014
- Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. Cancer immunology research. 1:309-319. 2013
- Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy. 5:1191-1206. 2013
- Panorama From the Oncolytic Virotherapy Summit. Molecular Therapy. 21:1814-1818. 2013
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines. OncoImmunology. 2:e26013-e26013. 2013
- Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunology. 6:612-625. 2013
- HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. Molecular Therapy. 21:887-894. 2013
- Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. Blood. 121:2432-2439. 2013
- Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine. Molecular Therapy. 20:1791-1799. 2012
- ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. Molecular Therapy. 20:1148-1157. 2012
- IL-15 Can Signal via IL-15Rα, JNK, and NF-κB To Drive RANTES Production by Myeloid Cells. Journal of Immunology. 188:4149-4157. 2012
- Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Therapy. 19:238-246. 2012
- Oncolytic viruses: a step into cancer immunotherapy. Virus Adaptation and Treatment. 4:1-1. 2011
- Vesicular Stomatitis Virus Oncolytic Treatment Interferes with Tumor-Associated Dendritic Cell Functions and Abrogates Tumor Antigen Presentation. Journal of Virology. 85:12160-12169. 2011
- Strategies to Enhance Viral Penetration of Solid Tumors. Human gene therapy. Clinical development. 22:1053-1060. 2011
- A critical role for IL‐15 in TLR‐mediated innate antiviral immunity against genital HSV‐2 infection. Immunology and Cell Biology. 89:663-669. 2011
- Targeting Tumor Vasculature With an Oncolytic Virus. Molecular Therapy. 19:886-894. 2011
- IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research. 71:2497-2506. 2011
- Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood. 117:2668-2680. 2011
- Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy. Molecular Therapy. 19:335-344. 2011
- Potentiating Cancer Immunotherapy Using an Oncolytic Virus. Molecular Therapy. 18:1430-1439. 2010
- FimH Can Directly Activate Human and Murine Natural Killer Cells via TLR4. Molecular Therapy. 18:1379-1388. 2010
- IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. Journal of Leukocyte Biology. 88:529-536. 2010
- A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Molecular Therapy. 18:1123-1129. 2010
- A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.. Molecular Therapy. 18:1123-1129. 2010
- Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Molecular Therapy. 18:888-895. 2010
- Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen. Journal of Immunology. 184:4269-4275. 2010
- Combining oncolytic virotherapy and tumour vaccination. Cytokine and Growth Factor Reviews. 21:143-148. 2010
- Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells. Cancer Immunology, Immunotherapy. 59:313-321. 2010
- Intelligent Design: Combination Therapy With Oncolytic Viruses. Molecular Therapy. 18:251-263. 2010
- Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus. Molecular Therapy. 17:1814-1821. 2009
- Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity. Molecular Therapy. 17:1465-1472. 2009
- Diplomatic immunity: turning a foe into an ally.. Current Opinion in Molecular Therapeutics. 11:13-21. 2009
- The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis. Journal of Virology. 83:552-561. 2009
- Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand. Journal of Immunology. 181:6702-6706. 2008
- Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response. Journal of Virological Methods. 153:276-279. 2008
- A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication. Molecular Therapy. 16:1437-1443. 2008
- Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine. Molecular Therapy. 16:1161-1169. 2008
- Cigarette Smoke Suppresses Type I Interferon-Mediated Antiviral Immunity in Lung Fibroblast and Epithelial Cells. Journal of Interferon and Cytokine Research. 28:167-179. 2008
- Mucosal Luminal Manipulation of T Cell Geography Switches on Protective Efficacy by Otherwise Ineffective Parenteral Genetic Immunization. Journal of Immunology. 178:2387-2395. 2007
- Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Molecular Therapy. 15:123-130. 2007
- Cigarette Smoke Impacts Immune Inflammatory Responses to Influenza in Mice. American Journal of Respiratory and Critical Care Medicine. 174:1342-1351. 2006
- Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV ΔM51 ) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute. 98:1546-1557. 2006
- Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif. Journal of General Virology. 87:3379-3384. 2006
- Induction of Innate Immunity against Herpes Simplex Virus Type 2 Infection via Local Delivery of Toll-Like Receptor Ligands Correlates with Beta Interferon Production. Journal of Virology. 80:9943-9950. 2006
- Vesicular Stomatitis Virus: A Potential Therapeutic Virus for the Treatment of Hematologic Malignancy. Human gene therapy. Clinical development. 15:821-831. 2004
- Vesicular stomatitis virus: re-inventing the bullet. Trends in Molecular Medicine. 10:210-216. 2004
- VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 4:263-275. 2003
- Getting oncolytic virus therapies off the ground. Cancer Cell. 4:7-11. 2003
- Oncolytic Viruses: Programmable Tumour Hunters. Current Gene Therapy. 2:243-254. 2002
- Identification of vesicular stomatitis virus as a leukemolytic agent. Blood. 96. 2000
- The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus. Journal of Virology. 74:9580-9585. 2000
- Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine. 6:821-825. 2000
- Exon-skipping in BCR/ABL is induced by ABL exon 2. Biochemical Journal. 348:63-69. 2000
- Expression of p210 and p190 BCR‐ABL due to alternative splicing in chronic myelogenous leukaemia. British Journal of Haematology. 103:711-715. 1998
- Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies.. Leukemia. 10:1370-1376. 1996
- Dysregulation of HOX11 by Chromosome Translocations in T-cell Acute Lymphoblastic Leukemia: A Paradigm for Homeobox Gene Involvement in Human Cancer. Leukemia and Lymphoma. 16:209-215. 1995
- Characterization of the Shope Fibroma Virus DNA Ligase Gene. Virology. 202:642-650. 1994
-
preprints
- Safety and immunopotency of an adenovirus-vectored tuberculosis vaccine delivered via inhaled aerosol to healthy humans: a dose and route comparison phase 1b study 2021
- Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2 2021